Although anti-programmed death 1 (PD-1)/programmed death ligand-1(PD-L1) drugs have achieved considerable clinical efficacy and durable response with low toxicity (45, 46), they are not effective for all cancer types or do not achieve ideal efficacy in all patients (47). Here, CD274 is linked to cancer.